Clinical Trials Browser

Phase 1 × Cytarabine × Tumor-Agnostic × Clear all

NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Phase 1 Terminated

Neoplasm, Residual